The largest database of trusted experimental protocols

2 protocols using pc 9 cells

1

Establishing Crizotinib-Resistant Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
HCC78 cells harboring the SLC34A2‐ROS1 fusion gene were kindly provided by Dr William Pao (Vanderbilt University, Nashville, TN, USA). ABC‐20 cells were established in our laboratory from pleural effusion obtained from a Japanese male former smoker who had lung adenocarcinoma harboring the CD74‐ROS1 fusion gene. The experiment regarding ABC‐20 cells was approved by the Institutional Review Board of Okayama University Hospital. Written informed consent was obtained from the patient. PC‐9 cells harboring EGFR 19 del E746_A750 were purchased from the European Collection of Cell Cultures (Salisbury, UK). 293T cells were purchased from the RIKEN Cell Bank (Ibaragi, Japan). Cells were cultured in RPMI 1640 medium (Sigma‐Aldrich, St. Louis, MO, USA) supplemented with 10% heat‐inactivated FBS and 1% penicillin/streptomycin in a tissue culture incubator at 37°C with 5% CO2. To establish a crizotinib‐resistant cell line, HCC78 cells were treated with gradually increasing concentrations of crizotinib, starting at .2 μmol/L (lower than the IC50 of HCC78 cells). After 4 months, the cells grew in the presence of 2 μmol/L crizotinib and were designated as HCC78R cells. HCC78R cells were maintained in culture medium containing 1 μmol/L crizotinib. The resistant cell lines were tested using the PowerPlex 16 STR System (Promega Corporation, Madison, WI, USA).
+ Open protocol
+ Expand
2

Establishing EGFR-mutant Cell Lines and Evaluating Inhibitor Sensitivity

Check if the same lab product or an alternative is used in the 5 most similar protocols
PC-9 cells (EGFR Ex19 del E746_A750) were purchased from the European Collection of Cell Cultures in 2014. RPC-9 cells (Gefitinib-resistant; EGFR Ex19 del E746_A750 and Ex20 T790M) were established from a parental PC-9 cell line in our laboratory18 (link). HCC827 cells (EGFR Ex19 del E746_A750)5 (link) and PC-9/BRc1 cells (afatinib-resistant; EGFR Ex19 del E746_A750 and Ex20 T790M)19 (link) were kindly provided by Dr. William Pao (Vanderbilt University, Nashville, TN, USA). Cells were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin in a tissue culture incubator at 37 °C under 5% CO2.
Naquotinib was provided by Astellas Pharma Inc. (Tokyo, Japan) under a material transfer agreement. Gefitinib, afatinib, osimertinib, crizotinib, SGX-523, selumetinib, and trametinib were purchased from Selleck Chemicals (Houston, TX, USA). UNC569 was purchased from Merck Millipore (Billerica, MD, USA). All compounds were dissolved in dimethyl sulfoxide for in vitro studies.
Growth inhibition was measured using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay20 (link). Briefly, cells were plated onto 96-well plates at a density of 2,000–3,000 per well and continuously exposed to each drug for 96 h.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!